Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 15, 2022
Event: Completion of the sale of substantially all assets related to the Pathogen Detection Systems (PDS) line of business to BWSI, LLC.
Key Financial Metrics
The filing does not provide specific historical revenue, profit, cash flow, or debt figures for the reporting period. Financial impact details are limited to the transaction terms:
- Transaction Consideration: BWSI made a nominal cash payment at closing.
- Liabilities: BWSI assumed certain liabilities of the PDS Business effective from the closing date.
- Future Revenue Stream: Nephros is entitled to an annual royalty for seven years (January 1, 2023, to December 31, 2029). The royalty equals a specified percentage of the gross margin BWSI receives from sales and licensing of PDS products.
Material Changes
The primary material change is the divestiture of the PDS Business. This transaction alters the Company's asset base and future revenue model by replacing direct operations in this segment with a royalty-based income stream. Unaudited pro forma condensed financial information reflecting this sale is included as Exhibit 99.1.
Guidance, Outlook, and Risks
Outlook: The Company anticipates future income from the PDS Business solely through the royalty agreement described above. No specific financial guidance or earnings outlook is provided in this filing.
Risks/Contingencies: Future royalty payments are contingent upon BWSI's ability to generate gross margin from the sale and licensing of the acquired products. The filing references the full Purchase Agreement for detailed terms and redacted information.
Investor Verification Checklist
- Review Exhibit 99.1 for the unaudited pro forma financial impact of the divestiture.
- Examine Exhibit 2.1 (Agreement for Purchase and Sale of Assets) to determine the specific royalty percentage and definitions of "gross margin."
- Verify the specific liabilities assumed by BWSI to understand the extent of Nephros's remaining obligations.
- Assess the strategic rationale for retaining only royalty rights versus maintaining operational control of the PDS Business.